Skip to content
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Subscribe to our news
Contact
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Subscribe to our news
Contact
Contact
Subscribe
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Subscribe to our news
Contact
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Subscribe to our news
Contact
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
Media
May 13, 2025: Microbiome-Targeting Therapy MaaT033 Continues to Show Promise in Final Phase 1 Readout – Neurology Live
Date : May 13, 2025
Lien vers le média
Previous Post
May 12, 2025: 3 Questions à MaaT Pharma – Direct Dirigeants (subtitled in English)
Next Post
May 13, 2025: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025